首页|瑞舒伐他汀钙治疗老年冠心病合并高脂血症的疗效

瑞舒伐他汀钙治疗老年冠心病合并高脂血症的疗效

扫码查看
目的 探讨使用瑞舒伐他汀钙治疗老年冠心病合并高脂血症的疗效.方法 选取2016年1月~2017年1月我方医院收治的老年冠心病合并高脂血症的患者86例,采用随机数字表法,均分为2组,对照组43例患者给与阿托伐他汀钙治疗,观察组43例患者给与瑞舒伐他汀钙治疗,对比2组患者血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)和低密度脂蛋白(LDL-C),评价治疗效果.结果 根据治疗结果分析,观察组血脂改善程度明显优于对照组,对比差异有统计学意义(P<0.05),2组患者用药后无严重副反应.结论 瑞舒伐他汀钙治疗老年冠心病合并高脂血症效果显著,可显著改善患者血脂程度,较于辛伐他汀治疗见效更快,疗效更优,安全不良反应少.
Efficacy of rosuvastatin calcium in the treatment of elderly patients with coronary heart disease with hyperlipidemia
Objective To explore the curative effect of using rishuvastatin calcium in treatment of elderly coronary heart disease with hyperlipidemia. Methods From January 2016 to January 2017 in our hospital treated 86 cases of senile coronary heart disease (CHD) combined hyperlipidemia patients, using the random number table method, were divided into two groups, control group to 43 patients were given atorvastatin calcium treatment, 43 patients were given observation group shu calcium cut statin therapy, compared two groups of patients with serum total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL - C) and low density lipoprotein (LDL-C), and evaluate the effect of the treatment. Results According to the analysis of the treatment results, the improvement of blood lipid in the observation group was significantly better than the control group, and the difference was statistically significant (P<0.05), and the two groups did not have severe side effects after medication. Conclusion Calcium rui shu cut statin treatment of senile coronary heart disease (CHD) combined hyperlipidemia effect significantly, can significantly improve patients with blood lipid level, the statin treatment effect in cin drallig logging, faster, better curative effect, less adverse reaction and safety value of the clinical promotion and wide application.

rosuvastatinatorvastatin calciumblood lipidsserum cholesterolelderly coronary heart disease

郑庆厚、刘君、王震、高磊、谭慧莲、刘凌

展开 >

河北医科大学第一医院 心内二科,河北 石家庄 050000

瑞舒伐他汀 阿托伐他汀钙 血脂 血清胆固醇 老年冠心病

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(11)
  • 8